Decheng Capital
德诚资本
Decheng Capital (德诚资本) shows up in elsewhere's corpus only as a life-sciences investor appearing on other firms' deal announcements — there's no dedicated profile of the fund itself in the material. What the coverage does show: in September 2025 it doubled down as an existing shareholder in YolTech Therapeutics' (尧唐生物) 300M+ RMB Series B, led by the AstraZeneca-CICC Medical Industry Fund , and in March 2026 it co-led Syneron Bio's $150 million Series B alongside CDH VGC, with ADIA's subsidiary, Temasek-backed Seviora-affiliated capital, Qiming Venture Partners and others following . Both deals are biotech, suggesting a healthcare focus, but elsewhere's corpus doesn't cover the fund's founding, size, or team — so a fuller profile isn't possible from this material.
AI-generated — may contain errors, please verify.
Coverage
5Y News | Syneron Bio Closes $150 Million Series B Round
Syneron Bio today announced the completion of its Series B funding round.
YolTech Therapeutics Raises Over RMB 300 Million in Series B Led by AstraZeneca CICC Medical Industry Fund | Unity Ventures Portfolio News
The biopharmaceutical company with the most in-vivo gene-editing drug candidates in clinical-stage pipelines globally
Gaorong Monthly · December | Gaorong Ventures and Its Frontier Tech / Consumer / Healthcare / Enterprise Service Portfolio Companies Win Multiple Annual Awards
Its technological and innovative capabilities have won recognition.
Hangzhou Andao Pharma Closes $50 Million Series B to Advance Drug Development for Kidney Disease and Cancer
Addressing the enormous unmet clinical needs in nephrology and oncology.
